Aprepitant for Postoperative Nausea and Vomiting
For preventing postoperative nausea and vomiting in adults undergoing surgery, administer aprepitant 40 mg orally within 3 hours prior to induction of anesthesia as part of a multimodal antiemetic regimen. This is the FDA-approved dosing for PONV prophylaxis 1.
Dosing Regimen
The recommended approach is:
- Single dose: 40 mg orally within 3 hours before anesthesia induction 1
- Can be administered with or without food 1
- Swallow capsules whole 1
This differs substantially from the chemotherapy-induced nausea regimen (125 mg day 1, then 80 mg days 2-3), which should not be used for surgical patients 2.
Role in Multimodal Prophylaxis
Aprepitant functions as a second-line or adjunctive agent for high-risk patients, not as first-line monotherapy. The most recent ERAS guidelines (2026) for cesarean delivery and 2019 guidelines for colorectal surgery establish the framework 3:
First-Line Agents (Use These First):
- 5-HT3 antagonists (ondansetron, palonosetron)
- Dexamethasone (4-8 mg single dose)
- Dopamine antagonists (droperidol)
These provide ~25% relative risk reduction each, with combination therapy superior to monotherapy 4.
When to Add Aprepitant:
Reserve aprepitant (as an NK-1 antagonist) for patients with ≥2 PONV risk factors 4. However, the evidence shows aprepitant has not been demonstrated superior to ondansetron for PONV prevention 4. The 2019 ERAS colorectal guidelines explicitly state this limitation 4.
Evidence Quality and Limitations
The evidence supporting aprepitant for PONV is mixed:
Supporting evidence:
- Meta-analysis showed aprepitant 40 mg and 80 mg reduced vomiting 0-24 hours postoperatively (OR 0.40 and 0.32 respectively) 5
- Reduced PONV from 70% to 39% in joint arthroplasty, with shorter hospital stays 6
- Decreased nausea by 41.6% after bariatric surgery when added to multimodal regimen 7
Contradictory evidence:
- No significant PONV reduction in high-risk breast cancer patients (Apfel score 3-4) receiving aprepitant 80 mg plus dexamethasone/palonosetron versus placebo plus dexamethasone/palonosetron 8
- No benefit in endoscopic skull base surgery (42.9% vs 43.2% PONV rates) 9
- No benefit in acoustic neuroma surgery 10
The most recent high-quality guideline evidence (2026 ERAS cesarean delivery) does not specifically recommend aprepitant, instead emphasizing 5-HT3 antagonists, dopamine antagonists, and dexamethasone combinations 3.
Risk Stratification Approach
For patients with 1-2 risk factors: Use 2-drug combination from first-line agents (5-HT3 antagonist + dexamethasone) 4
For patients with ≥2 risk factors: Consider 2-3 antiemetics from different classes 4. Aprepitant may be added as a third agent, though evidence of superiority is lacking 4.
Common PONV risk factors include:
- Female sex
- Non-smoking status
- History of PONV or motion sickness
- Use of volatile anesthetics
- Postoperative opioid use
- Type of surgery (bariatric, laparoscopic, ENT procedures)
Important Safety Considerations
Drug Interactions (Critical):
Aprepitant is a CYP3A4 substrate, moderate inhibitor, and inducer 1:
- Contraindicated with pimozide (risk of QT prolongation) 1
- Monitor INR closely if patient on warfarin (check at 7-10 days post-dose) 1
- Reduces hormonal contraceptive efficacy - advise backup contraception for 28 days after dose 1
- Interactions with CYP3A4 substrates (many chemotherapy agents, some benzodiazepines) 2
Adverse Effects:
Generally well-tolerated with mild side effects including headache, constipation, fatigue, and dyspepsia 1.
Clinical Pitfalls to Avoid
Do not use chemotherapy dosing (125/80/80 mg) for surgical patients - the PONV dose is 40 mg single dose only 1
Do not use aprepitant as monotherapy - always combine with other antiemetic classes 4
Do not assume superiority over standard agents - evidence shows it is not better than ondansetron alone 4
Do not use for treatment of established PONV - only indicated for prophylaxis 1
Avoid chronic continuous dosing - not studied and drug interaction profile may change 2
Practical Algorithm
Step 1: Assess PONV risk factors (count: female, non-smoker, history PONV/motion sickness, volatile anesthetics planned, opioids planned)
Step 2:
- 0-1 risk factors: Consider single first-line agent or no prophylaxis
- 1-2 risk factors: Use 2-drug combination (5-HT3 antagonist + dexamethasone)
- ≥2 risk factors: Use 2-3 drugs from different classes
Step 3: If using 3-drug regimen for high-risk patient, aprepitant 40 mg may be added to 5-HT3 antagonist + dexamethasone, though evidence of added benefit is uncertain
Step 4: If breakthrough PONV occurs despite prophylaxis, use rescue antiemetic from different class than prophylaxis agents 4